Factors associated with successful weight loss after liraglutide treatment for obesity.

ABSTRACT:

Aim

To identify patient factors, including gastrointestinal functions, that are predictive or associated with weight loss in response to once-daily 3 mg liraglutide administered subcutaneously (SQ) or placebo in obesity.

Methods

One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily. Gastrointestinal functions were measured at baseline and 16 weeks: gastric emptying of solids (GET_1/2 ); fasting and postprandial gastric volumes; kcal ingested during ad libitum buffet meal and the nutrient drink test. GET_1/2 was also measured at 5 weeks. A multiple variable regression model examined variables associated with weight loss of more than 4 kg at 16 week

SUBMITTER: Sannaa W 

PROVIDER: S-EPMC9812862 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature